Pacific Biosciences Of California
0.0 %
-42.79 %
Yet to be announced
Company Overview
Pacific Biosciences of California is a biotechnology company that designs, develops, and manufactures advanced sequencing solutions for genomic analysis. The company's core technology is its Single Molecule, Real-Time (SMRT) sequencing, which enables the observation of natural DNA synthesis in real-time. Their products are used in various applications including de novo genome assembly, genetic disease research, plant and animal sciences, and microbiology.
The company primarily generates revenue through the sale of its sequencing instruments, consumables, and services to research institutions, pharmaceutical companies, and clinical laboratories.
Revenue Sources
PassBased on SEC filings and company reports, Pacific Biosciences generates its revenue primarily from the sale of DNA sequencing systems and associated consumables, as well as service and support for these products. These products and services are used for scientific research and medical purposes, which are permissible activities under Islamic law. There is no evidence of revenue from haram sources.
Reliance on Interest
| Reporting Date | Total Revenue | Total Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Dec. 31, 2024 | $193.24m | $195.01m | - | $2.76m | 0.00% | 1.41% |
| Sept. 30, 2024 | $39.97m | $107.58m | - | $3.54m | 0.00% | 3.29% |
| June 30, 2024 | $36.01m | $215.4m | - | $3.54m | 0.00% | 1.64% |
| March 31, 2024 | $38.81m | $123.75m | - | $3.58m | 0.00% | 2.89% |
The company has consistent interest expenses across all four quarters, ranging from approximately $3.5 million to $3.6 million per quarter. These expenses are material when compared to the company's revenue and total expenses, particularly given the company's pre-profit status and significant R&D investments. However, since the company is still in its growth phase and heavily focused on research and development, we skip this check as per our methodology for pre-mature companies.
Operational Ethics
PassAfter reviewing the company's operations, partnerships, and locations, there is no evidence of significant ongoing associations with entities involved in human rights violations. The company's primary operations are based in the United States, and its international presence appears to be focused on legitimate scientific and commercial activities.
Comments